PMID- 18264744
OWN - NLM
STAT- MEDLINE
DCOM- 20090203
LR  - 20141120
IS  - 1880-4233 (Electronic)
IS  - 1340-6868 (Linking)
VI  - 15
IP  - 3
DP  - 2008
TI  - Tyrosine1248-phosphorylated HER2 expression and HER2 gene amplification in female 
      invasive ductal carcinomas.
PG  - 231-40
LID - 10.1007/s12282-007-0026-8 [doi]
AB  - BACKGROUND: Phosphorylated HER2 (pHER2) may more accurately reflect the signaling 
      and functional activity of the HER2 protein than detection of HER2 itself. The 
      detection of HER2 gene amplification using fluorescence in situ hybridization 
      (FISH) provides superior prognostic information for the diagnosis of breast 
      cancer. However, the relationship between pHER2 expression in tissue samples and 
      HER2 gene amplification remains unclear. METHODS: A total of 210 cases were 
      recruited. The expression of HER2 and tyrosine (Tyr)1248-pHER2 was investigated 
      by immunohistochemistry, and HER2 gene amplification was analyzed by FISH. 
      Spearman's rank correlation test was employed to confirm correlation between HER2 
      and Tyr1248-pHER2. Chi-square and Student's t test were used to determine a 
      significant difference between the baseline characteristics of tumors and the 
      FISH, HER2 and Tyr1248-pHER2 results. The phosphorylation rate of HER2 was 
      calculated using a digital-analysis system. RESULTS: HER2 expression was 
      significantly (P < 0.001) associated with Tyr1248-pHER2 expression. HER2 gene 
      amplification could be detected in 55 (26.2%) of the 210 tumors; 40 were HER2 
      positive and 32 were Tyr1248-pHER2 positive. The sensitivity and specificity of 
      HER2 and Tyr1248-pHER2 for HER2 gene amplification were 72.7 and 58.2%, and 91.6 
      and 95.5%, respectively. In cases with an HER2 score of 2, and a phosphorylation 
      score of 2 or 3, gene amplification was observed in 4 (80.0%) out of 5 tumors. 
      CONCLUSIONS: Tyr1248-pHER2 expression is highly specific for HER2 gene 
      amplification. The phosphorylation status might provide an adjunct to the 
      assessment of gene amplification in patients with an HER2 score of 2.
FAU - Taniyama, Kiyomi
AU  - Taniyama K
AD  - Institute for Clinical Research, National Hospital Organization Kure Medical 
      Center and Chugoku Cancer Center, 3-1 Aoyama-cho, Kure 737-0023, Japan. 
      taniyamak@kure-nh.go.jp
FAU - Ishida, Katsunari
AU  - Ishida K
FAU - Toda, Tamaki
AU  - Toda T
FAU - Motoshita, Junichi
AU  - Motoshita J
FAU - Kuraoka, Kazuya
AU  - Kuraoka K
FAU - Saito, Akihisa
AU  - Saito A
FAU - Tani, Yoichi
AU  - Tani Y
FAU - Uike, Toshinori
AU  - Uike T
FAU - Teramoto, Seiichi
AU  - Teramoto S
FAU - Koseki, Masato
AU  - Koseki M
LA  - eng
PT  - Journal Article
DEP - 20080209
PL  - Japan
TA  - Breast Cancer
JT  - Breast cancer (Tokyo, Japan)
JID - 100888201
RN  - 42HK56048U (Tyrosine)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Breast Neoplasms/*genetics/*metabolism/pathology
MH  - Carcinoma, Ductal, Breast/genetics/metabolism/secondary
MH  - Female
MH  - *Gene Amplification
MH  - Genes, erbB-2/*genetics
MH  - Humans
MH  - Immunoenzyme Techniques
MH  - In Situ Hybridization, Fluorescence
MH  - Middle Aged
MH  - Phosphorylation
MH  - Receptor, ErbB-2/*metabolism
MH  - Tyrosine/*metabolism
EDAT- 2008/02/12 09:00
MHDA- 2009/02/04 09:00
CRDT- 2008/02/12 09:00
PHST- 2007/03/09 00:00 [received]
PHST- 2007/09/10 00:00 [accepted]
PHST- 2008/02/12 09:00 [pubmed]
PHST- 2009/02/04 09:00 [medline]
PHST- 2008/02/12 09:00 [entrez]
AID - 10.1007/s12282-007-0026-8 [doi]
PST - ppublish
SO  - Breast Cancer. 2008;15(3):231-40. doi: 10.1007/s12282-007-0026-8. Epub 2008 Feb 
      9.